Kristof Vercruysse on ”First in Human” Presented at ASH25
Kristof Vercruysse, CEO and Co-Founder at TargED Biopharmaceuticals, reposted from TargED Biopharmaceuticals on LinkedIn:
”Back in town from ASH25.
What a journey and emotional rollercoaster it has been the last days.
Thanks to the full TargED team to make the First in Human happen with positive results and looking forward for more to come.”
Quoting TargED Biopharmaceuticals‘s post:
”We are excited to announce positive results from a Phase 1 study for TargED’s lead investigational thrombolytic fusion protein, TGD001, in an oral presentation at ASH25 in Orlando, Florida today.
The first-in-human clinical trial demonstrated that TGD001 is safe and was well tolerated with no spontaneous bleeding events across four ascending dose cohorts.
TargED Biopharmaceuticals plans to initiate two Phase 1/2 clinical proof-of-concept studies evaluating TGD001 as a potential treatment for patients with acute ischemic stroke (AIS) and thrombotic microangiopathies (TMAs), including immune thrombotic thrombocytopenic purpura (iTTP).
Read the full press release with detailed results.
Stay updated with Hemostasis Today.
-
Mar 17, 2026, 18:11Ossama Mansour: Landmark MENA Guidelines for Acute Ischemic Stroke Management
-
Mar 17, 2026, 17:48Andrea Van Beek: Improving DOAC Adherence Saves Lives
-
Mar 17, 2026, 17:43Soumen Bhattacharyya: Microangiopathic Hemolytic Anemia Is Often a Hematologic Clue to Underlying Malignancy
-
Mar 17, 2026, 17:37Peter Bou Dib: New Insights on Factor VIII and the Musculoskeletal System
-
Mar 17, 2026, 17:31Armghan Ans: The 2026 Stroke Guidelines Are Excellent, Now the Hard Part
-
Mar 17, 2026, 17:26Danny Hsu: Navigating a Rebalanced Hemostatic State in Decompensated Cirrhosis
-
Mar 17, 2026, 17:21Matías J Alet on Acute Ischemic Stroke With Low NIHSS at NeuroQuality
-
Mar 17, 2026, 17:16S1PR4 Controls Platelet Fibrinogen Binding and Thrombus Formation – JTH
-
Mar 17, 2026, 15:55Mostafa Faisal Mohammed Saleh: Evidence-Based Recommendations for Hodgkin Lymphoma Management in LMICs